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EXPERIMENTAL STUDIES
Passivation of Metallic Stents After Arterial Gene Transfer of
phVEGF165 Inhibits Thrombus Formation and Intimal Thickening
ERIC VAN BELLE, MD, FERMIN O. TIO, MD*, DONGHUI CHEN, MD, LUC MAILLARD, MD,
DONGFEN CHEN, MD, MARIANNE KEARNEY, BS, JEFFREY M. ISNER, MD, FACC
Boston, Massachusetts and San Antonio, Texas
Objectives. This study sought to test the hypothesis that direct
gene transfer of an endothelial cell mitogen could passivate
metallic stents by accelerating endothelialization of the prosthe-
sis.
Background. Thrombosis and restenosis comprise the principal
clinical manifestations of compromised biocompatibility of endo-
vascular stents. Previous studies have demonstrated that endo-
thelial recovery at sites of balloon injury is a critical determinant
of consequent intimal thickening and mural thrombus. We there-
fore investigated the potential for an endothelial cell mitogen
delivered as plasmid DNA to optimize stent biocompatibility.
Methods. Naked plasmid DNA encoding vascular endothelial
growth factor (VEGF)/vascular permeability factor (VPF)
(phVEGF165) was delivered locally using a hydrogel-coated bal-
loon angioplasty catheter to 16 rabbit iliac arteries in which
metallic stents had been placed at the site of balloon injury; the
contralateral iliac artery of each rabbit was balloon injured and
stented but not transfected.
Results. Stent endothelialization was accelerated by phVEGF165
gene transfer (87.38 6 5.06% vs. 33.13 6 9.73% [mean 6 SEM] of
the planimetered stent surface in the treated vs. contralateral
limb, p 5 0.005). This was associated with a significant reduction
in mural thrombus (3.7 6 2.4% vs. 32.7 6 9.7%, p 5 0.01) at day
7 and intimal thickening (maximal intimal area 0.61 6 0.09 vs.
1.44 6 0.12 mm2, p < 0.0001) at day 28. No benefit was observed
from pCMV-luciferase in 14 similarly instrumented control rab-
bits.
Conclusions. These findings indicate that arterial gene transfer
of naked plasmid DNA encoding for an endothelial cell mitogen
may successfully passivate endovascular stents by accelerating
stent endothelialization, thereby reducing in-stent thombus and
obstruction due to intimal thickening.
(J Am Coll Cardiol 1997;29:1371–9)
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Two landmark clinical trials established endovascular stents as
the first mechanical intervention to have a favorable impact on
restenosis (1,2). In both trials, stents proved superior to
balloon angioplasty for primary lesions in arteries $3.0 mm in
diameter with good distal runoff. The success achieved in these
well defined anatomic cohorts has prompted investigations
designed to further optimize stent biocompatibility to broaden
the application of this promising technology.
Thrombosis and restenosis comprise the principal clinical
manifestations of compromised stent biocampatibility. The
incidence of thrombosis appears to have been greatly dimin-
ished by technical modifications (3), including the use of
intravascular ultrasound and high pressure balloon inflation,
both of which may optimize stent deployment. Restenosis has
been inferred to result most often from intimal proliferation,
and several promising strategies (4–8) have been proposed to
modify the frequency of this complication.
Gene therapy represents a potential strategy to optimize
biocompatibility of cardiovascular prostheses (9), including
stents. Certain features of gene therapy may be particularly
well suited for this application. The transfer of genetic material
to the arterial wall at the site of stent placement would create
the equivalent of a local depot effect for a period of days to
weeks. For most gene therapy strategies, the self-limited
nature of gene expression might well be sufficient to establish
biocompatibility, yet provide safety from unlimited, and per-
haps unnecessary, long-term unrestricted expression. Indeed,
novel gene therapy strategies have been proposed or tested in
conjunction with stent therapy (10–12).
We considered that direct gene transfer of the gene encod-
ing the endothelial cell mitogen, vascular endothelial growth
factor (VEGF) (13) could be an effective means of passivating
the blood/stent interface (i.e., rendering it more inert) and thus
augmenting stent biocompatibility. This strategy seeks to ex-
ploit certain features of VEGF.
1. It represents an extension of the principle that the
endothelium is, as described by Clowes (9), “the controlling
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element governing the function of biomaterials in the vascula-
ture.” Previous studies (14 –16) have demonstrated that
prompt endothelial recovery of the site of balloon-induced
endothelial disruption of native vessels could reduce intimal
thickening. Given the suggestion that in-stent restenosis results
principally from smooth muscle proliferation, expeditious en-
dothelialization of endovascular prostheses, including stents
(17), would be anticipated to confer similar benefits.
2. VEGF contains at its amino terminus the signal sequence
permitting active secretion by intact cells (18). Because previ-
ous work (19,20) had suggested that transfer of cDNA encod-
ing for secreted proteins may modulate the recipient pheno-
type despite a low transfection efficiency, this feature of VEGF
suggested the opportunity to perform gene transfer with naked
plasmid DNA, in lieu of adjunctive vectors.
The results of the present series of experiments demon-
strate that metallic stents may be successfully passivated by
gene transfer designed to achieve prompt endothelialization.
Direct anatomic inspection of the stent surface documented
accelerated endothelialization, which was associated with a
marked reduction in both in-stent thrombosis and restenosis.
These findings thus establish proof of the concept that gene
therapy may be used to enhance biocompatibility of endovas-
cular stents.
Methods
Animals. New Zealand White rabbits (5.0 to 5.5 kg) (Pine
Acre Rabbitry) were used exclusively for these experiments,
according to protocols approved by St. Elizabeth’s Institutional
Animal Care and Use Committee. All animals received aspi-
rin, 50 mg, daily for 7 days before the initial intervention and
until euthanasia. All procedures were performed under gen-
eral anesthesia and sterile conditions.
In vivo catheter procedures. A 5F introducer sheath
(Terumo) was positioned in the femoral artery under surgical
exposure, after which nitroglycerin (0.25 mg, SoloPak) and
heparin (1,000 United States Pharmacopeia U, Elkins-sinn)
were administered intraarterially. All catheters were subse-
quently introduced through this sheath and advanced to the
external iliac artery through a 0.014-in. guide wire (Advanced
Cardiovascular Systems). Arterial injury was performed using a
3F Fogarty balloon catheter (Baxter Edwards) (21). Stent
implantation was performed using a 15-mm long Palmaz-
Schatz coronary stent (Johnson & Johnson) delivered over an
angioplasty balloon catheter (Scimed); the stent was apposed
to the vessel wall using a balloon inflation pressure of 10 atm
to achieve a 1.1 to 1.2:1.0 stent/artery ratio (see Results).
Arterial gene transfer was performed immediately after stent
deployment as well as in nonstented iliac arteries as described
later.
Quantitative angiography. Baseline angiograms of the
external iliac arteries and radiographs of the stents after
implantation were obtained for each animal. Quantitative
analysis was performed using a computerized analysis system
(ImageComm) as previously described (22). In each vessel, the
stent/artery ratio was calculated as the ratio of the mean stent
diameter to the mean baseline angiographic lumen diameter.
Plasmid DNA. The phVEGF165 mammalian expression
vector used in these experiments contains the cDNA for
recombinant human VEGF165 under the transcriptional con-
trol of the cytomegalovirus (CMV) promoter/enhancer
(13,23). The plasmid pCMV-luciferase, containing the cDNA
for firefly luciferase, was used both to evaluate transfection
efficiency and as a control plasmid. The plasmid pGSV-LacZ
(courtesy of Dr. Claire Bonnerot) (24), containing a nuclear
targeted beta-galactosidase sequence coupled to the simian
virus 40 early promoter, was used to specify the location of the
transfected cells.
Catheter delivery of plasmid DNA. A conventional pipette
was used to apply plasmid DNA (10 mg/ml) to the 20-mm thick
layer of hydrogel polymer coating the external surface of an
angioplasty catheter (Boston Scientific) balloon (23). Once
dried, the balloon was deflated and withdrawn back into a 4F
protective sleeve. The catheter with its closely applied 4F
sleeve was then introduced through the indwelling 5F intro-
ducer sheath, advanced quickly to the external iliac artery and
inflated at 6 atm.
Gene transfer after stent implantation. To define a strat-
egy capable of achieving a level of protein production in
stented arteries equivalent to that observed in nonstented
arteries, a series of transfections using various doses of plasmid
DNA (400 to 800 mg) and inflation times (5 to 20 min) was
performed with pCMV-luciferase. Local gene transfer was
performed after stent deployment using the 2-cm long
hydrogel-coated balloon catheter previously described, after
which the animals were killed at day 3 for chemiluminescent
analysis of luciferase activity (n 5 4 in each group). These
results were compared with those obtained after a 5-min
transfection in nonstented iliac arteries.
To evaluate the time course of protein production in the
stented artery during the first week after gene transfer, rabbits
were killed at 36 h (n 5 4) and on day 7 (n 5 4) for
chemiluminescent analysis of luciferase activity. The stented
iliac arteries transfected with pCMV-luciferase were also eval-
uated morphometrically to determine the extent of stent
endothelialization (see later). These stented segments consti-
tuted an adjunct control group for analyzing the impact of
additional trauma created by local catheter delivery on stent
endothelialization.
The site of gene expression was studied in four animals
transfected with a plasmid encoding for nuclear targeted
beta-galactosidase (pGSV-LacZ) and killed at day 3. Beta-
galactosidase activity was determined by incubation with
Abbreviations and Acronyms
CMV 5 cytomegalovirus
RT-PCR 5 reverse transcription–polymerase chain reaction
VEGF 5 vascular endothelial growth factor
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5-bromo-4-chloro-3-indolyl beta-D-galactoside chromogen (X-
Gal, Sigma Corp.). After staining with X-Gal solution, arteries
were macroscopically examined and photographed. The
stented arterial segment was then sectioned, the stent removed
and the artery embedded in paraffin. Tissues were sectioned
and counterstained with hematoxylin-eosin. Histochemical
identification of beta-galactosidase within the cell nucleus was
interpreted as evidence for successful gene transfer.
Percutaneous arterial gene transfer of phVEGF165 after
stent implantation. In 30 rabbits, both external iliac arteries
underwent balloon injury followed by stent implantation. In 16
rabbits, percutaneous arterial gene transfer of 800 mg of
phVEGF165 was then performed in one stented artery (ran-
domly chosen) using a hydrogel coated balloon catheter, as
previously described. In 14 animals, one randomly selected
stented iliac artery was transfected with pCMV-luciferase
using an identical delivery strategy.
Previous studies (25) have suggested that the trauma asso-
ciated with local delivery of an inactive agent (e.g., saline or
reporter gene) could itself stimulate intimal thickening. Ac-
cordingly, to avoid establishing a negative bias among the
contralateral control arteries after stent deployment, no addi-
tional instrumentation was performed in the contralateral,
nontransfected arteries of any of these 30 animals.
The timepoints selected for necropsy examination were
based on quantitative analysis of stent endothelialization per-
formed previously in our laboratory using silver nitrate-stained
sections (see later) to identify endothelialization of stented
arterial segments (van Belle E., unpublished data). On day 0
(n 5 3), examination of the lumen surface disclosed no
measurable endothelialization. By day 4 (n 5 2), ,20% of the
stent was endothelialized. By day 7 (n 5 2), the extent of
endothelialization was still ,40% complete. By 4 weeks (n 5
3), stent endothelialization was typically complete. Because
spontaneous endothelialization remained quite limited at day
7, this time point was selected for analysis of early stent
endothelialization in 14 animals in the current study; the
remaining 16 rabbits were killed at day 28 post-stent implan-
tation.
Site specificity and time course of gene transfer after
stenting. To evaluate the site specificity and time course of
gene expression for phVEGF165, gene transfer of phVEGF165
was performed in six rabbits using the protocol described
earlier. Animals were killed at 36 h (n 5 2), 3 days (n 5 2) and
7 days (n 5 2). Transfected stented vessels, contralateral
nontransfected stented vessels and remote organs (brain,
heart, lung, liver, spleen, kidney, muscle, testes) were retrieved
and immediately frozen in liquid nitrogen. Expression of
phVEGF165 was evaluated using reverse transcription–
polymerase chain reaction (RT-PCR) (26). The sequences
of the primers used were 59-GAGGGCAGAATCATCAC-
GAAGT-39 (sense) and 59-TCCTATGTGCTGGCCTTGG-
TGA-39 (antisense). RT-PCR products were analyzed by 1.5%
agarose gel electrophoresis. DNA bands were visualized under
ultraviolet illumination after staining with ethidium bromide.
Histologic analysis. In preparation for euthanasia, a can-
nula was inserted into the lower abdominal aorta to perfuse in
situ a total of 100 ml of 5% dextrose solution with 100 U/ml of
heparin, followed by a solution of 0.25% silver nitrate for 20 s.
This was followed by a solution of 5% dextrose and then
pressure perfused at 100 mm Hg for 2 h with 10% buffered
formalin.
To analyze stent endothelialization as well as mural throm-
bosis, specimens were cut lengthwise and macrophotographed
with a Zeiss Tessovar System 3. One half was submitted for
scanning electron microscopy, and the other half was used for
morphometric studies of intimal surface endothelialization.
Measurements were carried out using Sigmascan morphomet-
ric software (Jandel Scientific) on an Intel/486-based personal
computer system. Integration of the microscope with the
computer through the digitizing tablet facilitated direct exam-
ination of the endothelial surface at magnifications ranging
from 253 to 1253. The theoretic surface area for a 15-mm
long stent with a deployed diameter of 3.0 mm is 141 mm2. The
half-stent used for planimetry was cut longitudinally, then
opened along the longitudinal cut. Because the stent could not
be completely flattened without jeopardizing tissue integrity,
quantitative analysis was confined to the continuous longitudi-
nal section of intima, which remained flat enough to permit
focusing the microscope. The mean area of this longitudinal
strip, located opposite the longitudinal stent incision and
traversing the entire length of the stent, was 29 mm2. Areas of
endothelialization and surface thrombus were both quantified
in mm2.
Figure 1. Time course of VEGF gene expression at
mRNA level from 36 h through 7 days after transfection.
Arrow indicates position of VEGF band at 258 base
pairs. Results shown here were obtained by RT-PCR
performed at 36 h (lanes 9 and 10), 3 days (lanes 11 and
12) and 7 days (lanes 13 and 14) on stented arteries
transfected with phVEGF165 (800 mg). Lane 1 5 nega-
tive control (no RNA); lane 2 5 negative control (PCR
of a VEGF-transfected stented artery, same as lane 13,
excluding reverse transcriptase reaction); lanes 3 to 8 5
gene expression in contralateral stented but nontrans-
fected arteries; lane 15 5 DNA size standards,
pGEM3zf(2) digested with Hae III.
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To confirm the extent of stent endothelialization, the
remaining half of the specimen was processed for scanning
electron microscopy using a modification of Peldri II sublima-
tion (27). The specimens were coated with gold/palladium,
after which scanning electron photomicrographs (403 to
5003) were then systematically obtained of the proximal,
medial and distal portions of each specimen.
For analysis of intimal thickening, specimens were embed-
ded in methyl methacrylate plastic (Sigma Corp.), cut at
500 mm with a low speed diamond wafer mounted on a Buelher
Isomet saw, stained on one side with metachromatic stain and
analyzed morphometrically as described earlier. Eight sections,
systematically retrieved from the length of the specimen,
were measured. For each section, the extent of vessel injury
caused by the stent struts was quantified using the method
described by Schwartz et al. (28), and the areas of the
neointima, media, total vessel and native lumen (delineated by
the internal elastic lamina) were determined. Percent cross-
sectional area narrowing was calculated for each section as
(Intimal area/Native lumen area) 3 100. For each specimen,
the highest value of neointimal area (Maximal neointimal
area) and percent cross-sectional area narrowing (Maximal
percent cross-sectional area narrowing) were used to investi-
gate the effects of phVEGF165 gene transfer.
Thrombotic occlusion. Thrombotic stent occlusion pre-
cluded the previously described quantitative analyses. Accord-
ingly, such specimens were not included in these analyses, and
the frequency of this event was analyzed separately (see
Results, Thrombotic occlusion).
Data analysis. Results are expressed as mean value 6
SEM. Differences between more than two mean values were
assessed using analysis of variance and the Scheffe´ F test for
multiple comparisons. A two-tailed paired Student t test was
used to compare group means for phVEGF165- or pCMV-
luciferase–transfected stented arteries versus contralateral
nontransfected control stented arteries. Correlations were
assessed using linear regression analysis; p , 0.05 was consid-
ered to denote statistical significance.
Results
Quantitative angiographic analysis. Baseline lumen diam-
eter was 2.60 6 0.06 mm. Diameter of the deployed stent
measured 3.07 6 0.05 mm. The resulting stent/artery ratio was
1.18 6 0.05. No differences were observed among groups.
Quantitative analysis of histologic injury. The extent of
vessel injury at the stent site (injury score) was 1.01 6 0.04 for
all groups; 1.07 6 0.07 for VEGF-transfected sites; 0.98 6 0.09
for the contralateral (nontransfected) artery of VEGF-
transfected rabbits; 1.04 6 0.08 for luciferase-transfected sites;
and 0.96 6 0.09 for the contralateral (nontransfected) artery of
luciferase-transfected rabbits. All differences were nonsignifi-
cant.
Arterial gene transfer after stenting requires a larger dose
of plasmid DNA. When arterial gene transfer was performed
with 400 mg of the reporter construct pCMV-luciferase deliv-
ered from a hydrogel balloon inflated for 5 min, gene expres-
sion in stented external iliac arteries was four- to fivefold
less than that for nonstented arteries. To achieve equivalent
protein expression in stented arteries required 800 mg of
plasmid DNA and an inflation time of 20 min. Accordingly, all
subsequent experiments used this protocol of arterial gene
transfer.
Time course and localization of reporter genes. The time
course of luciferase production after gene transfer in stented
iliac arteries demonstrated a detectable increase in protein as
early as 36 h after gene transfer that was sustained during the
following week.
In the 4 rabbits transfected with pGSV-LacZ, microscopic
examination of random sections performed within the stented
segment demonstrated 0 to 6 transfected vascular smooth
Figure 2. A, Quantification of stent endothelialization in iliac arteries
7 days after site-specific gene transfer of phVEGF165. Stent endo-
thelialization of arteries treated by site-specific gene transfer of
phVEGF165 was accelerated compared with that in the contralateral
arteries without gene transfer. No systemic effect of phVEGF165 was
detectable, as evidenced by the fact that stent endothelialization
achieved without gene transfer (No Gene Transfer) was similar
whether the contralateral stent site was transfected with pCMV-
luciferase (pCMV-luc) or phVEGF165. Although there was a trend for
instrumentation associated with gene transfer (pCMV-luc) to retard
endothelialization (vs. noninstrumented arteries in the contralateral
limb [No Gene Transfer]), this was not statistically significant. B,
Quantification of mural thrombus in stented iliac arteries 7 days after
site-specific gene transfer of phVEGF165. Mural thrombus was de-
creased after site-specific gene transfer of phVEGF165 compared with
that in the contralateral, nontransfected stent site (No Gene Transfer).
Instrumentation required for arterial gene transfer itself (pCMV-luc)
was no different from contralateral control (No Gene Transfer).
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cells/section in the superficial medial layer of the arterial wall
in all transfected vessels. Morphometric examination disclosed
a transfection efficiency of 0.12%.
Site-specificity of gene transfer with phVEGF165. RT-PCR
analysis of the stented iliac arteries transfected with phVEGF165
disclosed evidence of gene expression 36 h after gene transfer,
persisting through the first week (Fig. 1). No evidence of
similar gene expression was observed among the contralateral
stented (but nontransfected) iliac arteries (Fig. 1). RT-PCR
was also performed on sections from other organs and dis-
closed no evidence of gene expression at any site remote from
the VEGF-transfected arterial segment.
Site-specific phVEGF165 gene transfer accelerates stent
endothelialization. Seven days after phVEGF165 gene trans-
fer, stent endothelialization of the transfected segment was
significantly greater than that in the contralateral artery in
which a stent was deployed but no post-stent instrumentation
was performed (87.38 6 5.06% vs. 33.13 6 9.73% of the
planimetered stent surface, p 5 0.005) (Fig. 2A). Scanning
electron microscopic examination confirmed these findings
and, in the case of the VEGF-transfected segments, disclosed
features considered typical of mature neoendothelium, includ-
ing parallel lamellae of axially oriented spindle-shaped cells
(Fig. 3). Examination of the stented, nontransfected arterial
segment in the contralateral limb disclosed no evidence of
remote effects after site-specific phVEGF165 gene transfer.
Specifically, the extent of stent endothelialization in the non-
instrumented contralateral artery of rabbits treated with
phVEGF165 was no different from that observed in the con-
tralateral noninstrumented artery of rabbits treated with
Figure 3. Representative examples of spontaneous
stent endothelialization at day 7 (left) or after site-
specific gene transfer of phVEGF165 (right). Left
panels, Top panel shows a macrophotograph of the
silver-stained surface from the middle portion of
the stent (8.53). Stent endothelialization is incom-
plete (bottom), and mural thrombus is visible at the
stent struts. Scanning electron photomicrographs
from the proximal (5003), middle (3003) and
distal portions (3003) of the stent confirm incom-
plete stent endothelialization of the proximal and
distal portions of the stent with blood cell deposi-
tion in areas of nonconfluent endothelial cells
(distal), as well as thrombus along a nonendothe-
lialized strut segment (middle). Right panels, Top
panel shows a macrophotograph of the silver-
stained surface from middle portion of stent
(8.53). Stent endothelialization is virtually com-
plete; no mural thrombus is visible. Scanning elec-
tron photomicrographs from the proximal (3003),
middle (3003) and distal portions (3003) of the
stent confirm that a confluent endothelial cell
monolayer completely covers the stent (see Distal).
The endothelial cells appear arranged in direction
of the flow in the proximal part of the stent. No foci
of blood cells are visible.
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pCMV-luciferase (33.13 6 9.73% vs. 24.45 6 8.62%). Al-
though the percent of stent endothelialization at 7 days was
reduced by local catheter delivery itself (11.97 6 2.90% after
site-specific delivery of pCMV-luciferase to stented artery vs.
24.45 6 8.62% in the contralateral artery of pCMV-luciferase
animals in which no post-stent instrumentation was per-
formed), this did not achieve statistical significance (p 5 0.18).
Site-specific phVEGF165 gene transfer reduces develop-
ment of stent thrombus. Acceleration of stent endothelializa-
tion after site-specific transfection with phVEGF165 was asso-
ciated with less mural thrombus. Indeed, by day 7 after gene
transfer, 3.71 6 2.39% of the stent at the site of phVEGF165
gene transfer was covered with mural thrombus versus 32.66 6
9.68% of the contralateral stent in which no post-stent instru-
mentation was performed (p 5 0.01) (Fig. 2B). These quanti-
tative results were confirmed by scanning electron microscopy
(Fig. 3). A significant and inverse linear relation could be
demonstrated between the extent of the stent endothelializa-
tion and the extent of thrombus covering the stent surface (r 5
0.74, F 5 23.4, p , 0.0001).
Arterial gene transfer of phVEGF165 attenuates intimal thick-
ening within stent. Four weeks after site-specific phVEGF165
gene transfer, the maximal intimal area within the stent was
significantly lower (0.61 6 0.09 mm2) than that in the
contralateral artery in which no post-stent instrumentation was
performed (1.44 6 0.13 mm2, p , 0.0001) (Fig. 4A). In
contrast, site-specific delivery of a control plasmid (pCMV-
luciferase) had no significant impact on intimal thickening
compared with the contralateral artery in which no post-stent
instrumentation was performed (1.56 6 0.16 vs. 1.43 6
0.12 mm2, p 5 NS) (Fig. 4A). Maximal percent cross-sectional
area narrowing was also reduced to 12.96 6 1.78% in the
stented artery treated by site-specific delivery of phVEGF165
versus 32.29 6 3.63% in the stented contralateral artery
without post-stent instrumentation (p , 0.0001) (Fig. 4B). The
site-specific delivery of a control plasmid (pCMV-luciferase)
had no significant impact on this index (33.20 6 4.06% vs.
31.75 6 2.95%, p 5 NS) (Fig. 4B). Representative photomi-
crographs of histologic cross-sections retrieved at necropsy
from the stented arterial segments are shown in Figure 5.
Thrombotic occlusion was not observed in stents after
phVEGF165 gene transfer. Thrombotic occlusion was a rare
event in this series of experiments (4 [5.80%] of 69 stented
vessels). No instance of thrombotic occlusion was observed in
the stented vessels treated with phVEGF165 (0 [0%] of 16).
The only instances of thrombotic occlusion were observed in
the control vessels (4 [7.55%] of 53), including transfection
with a control plasmid (pCMV-luciferase: 1 [7.14%] of 14) or
no gene transfer (3 [7.69%] of 39).
Discussion
The results of these experiments demonstrate that gene
therapy may be used to passivate endovascular prostheses and
thereby enhance their biocampatibility in arteries that are
currently considered suboptimal for such devices. In particular,
this study has shown that 1) plasmid DNA may be successfully
transferred to the arterial wall after deployment of a metallic
stent; 2) the dose of plasmid DNA required to achieve a
particular level of reporter gene product (luciferase) is nearly
twofold that required in the absence of a stent; 3) stent
endothelialization may be achieved promptly (87% complete
by 7 days); 4) thrombus adherent to the stent struts may be
substantially reduced; and 5) intimal thickening of the stent
may be markedly diminished.
Naked plasmid DNA. The gene transfer strategy used in
the current study utilized so-called naked DNA (i.e., plasmid
DNA unaccompanied by adjunctive, including viral vectors).
Despite a nearly twofold increase in dose (800 mg) and an
increase in the duration of transfection time (20 min), analysis
of tissues or organs remote from the site of gene transfer
disclosed no evidence for loss of site specificity. Specifically,
RT-PCR demonstrated no evidence of gene expression at any
Figure 4. Intimal hyperplasia 4 weeks after site-specific gene transfer
of phVEGF165. Maximal intimal area (A) and the maximal percent
cross-sectional area (B) were reduced in stented arterial segments
transfected with phVEGF165. No differences were observed among the
other groups. *p , 0.0001 versus contralateral. Solid bars 5 gene
transfer; hatched bars 5 no gene transfer. pCMV-Luc 5 pCMV-
luciferase.
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of these sites. This finding is presumably due in large part to
the use of naked DNA, so that any plasmid that escapes into
the circulation during the process of gene transfer is rapidly
degraded by circulating nucleases. The precise basis for the
increased dose of plasmid DNA required after stent deploy-
ment has not yet been elucidated. However, we may speculate
that it is related to mechanical issues regarding the interface of
the catheter delivery device, the metallic stent and the lumen
surface of the vessel wall.
Accelerated reendothelialization. Endothelialization after
phVEGF165 was nearly complete by 7 days. Pilot studies
performed previously in our laboratory demonstrated that a
period of 4 weeks is typically required in the same animal
model as that used here to achieve spontaneous endotheliali-
zation of the lumen surface over the site of the 15-mm long
slotted metallic stent used here. In contrast to anatomic
evidence of endothelialization, the current study was not
designed to directly determine bioactivity of the neoendothe-
lium. Previous studies (29,30) have documented that functional
restoration of endothelium-dependent vasomotor reactivity is
typically delayed for up to 12 weeks after spontaneous reen-
dothelialization of a balloon-denuded artery. The reduction in
mural thrombus and intimal thickening observed within the
stented arterial segment as early as 2 weeks after gene transfer
in the current study constitute inferential evidence of expe-
dited recovery of endothelial functions responsible for regu-
lating these dual pathologic processes.
Reduced thrombus formation. The reduction in thrombus
observed in the phVEGF165 group is consistent with those
studies (31) that have demonstrated that endothelial cells
elaborate a variety of anticoagulant, antithrombotic proteins.
Although certain technical modifications in stent deployment
appear to have reduced the incidence of thrombotic occlusion
of the metallic stent used here (3), nonocclusive mural throm-
bus may contribute to stent restenosis by forming the substrate
for those infiltrating cells that populate and secrete extracel-
Figure 5. Effect of phVEGF165 on intimal hyperplasia. A (53),
Cross-section of transfected artery 4 weeks after stent implantation
and site-specific delivery of 800 mg of phVEGF165. Note limited intimal
hyperplasia. Cross sections of nontransfected artery (B [53]) and
pCMV-luciferase–transfected arteries (C and D [53]) are shown
for comparison. Note in panel D the persistence of organized throm-
bus.
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lular matrix for the stent neointima. Moreover, the reduction
in clinical evidence of stent thrombosis has been typically
accomplished in arteries $3.0 mm in diameter; adjunctive
phVEGF165 gene transfer may potentially extend the use of
such stents to arteries ,3.0 mm in diameter (native lumen
diameter of arteries in the present study was 2.60 6 0.06 mm),
as well as arterial sites with unfavorable anatomic features,
such as heavy calcific deposits or tapering lumen diameter,
where the risks associated with high pressure balloon inflation
may be increased (32).
Reduced neointimal thickening. The reduction in intimal
thickening observed here is also consistent with previous
investigations that have established the role of the endothe-
lium in modulating intimal hyperplasia (33) and associated
accumulation of extracellular matrix (34). Studies designed to
determine directly (35–37) or indirectly (6,7,38) the basis for
stent restenosis have suggested that this is most frequently due
to intimal hyperplasia. Recent analysis of tissue specimens
retrieved by directional atherectomy from patients with stent
restenosis in our own institution have documented evidence of
hypercellularity or augmented proliferative activity in seven of
eight patients (39). The reduced intimal thickening achieved
indirectly with phVEGF165 compares favorably with direct
antiproliferative gene transfer strategies reported previously
(40–44).
Alternative strategies for expediting reendothelialization.
The current experiments did not address either of two alter-
native strategies: gene therapy performed before stent deploy-
ment or the use of recombinant protein. Concerning the latter,
encouraging preliminary experience with bioactive, coated
metallic stents (4,8) suggests that protein administration is
indeed a viable alternative. In the case of VEGF, the non-
available status of the recombinant protein for human appli-
cation makes this currently a moot point. However, should
the protein be made available for human testing, it will be
intriguing to compare the effects of VEGF delivered at a
presumably low dose over a period of ;14 days (based on
results in the current study) from an actively expressing
transgene with single application of the locally delivered
recombinant protein.
The potential use of gene therapy as a strategy designed to
optimize the biocompatibility of endovascular stents may or
may not apply equally well to atherosclerotic arteries or all
stent designs. Furthermore, this approach must also be con-
sidered within the context of alternative strategies that have
shown promise both for reducing the frequency of stent
thrombosis and stent restenosis, certain of which are currently
in early clinical trials. The absence of occlusive thrombus
shown in the current study has also been achieved with high
dose heparin-coated stents (45). Reduced intimal hyperplasia
achieved indirectly in the VEGF-transfected arteries has also
been achieved with application of local irradiation (6,7,38).
However, when the stent was designed to serve itself as the
source of radioactivity, such radioactive stent wires have been
found to decrease endothelial cell proliferation in vitro (46)
and, more recently, in vivo (5,38). The implication of these
latter observations for the role of the endothelium in attenu-
ating restenosis awaits further study.
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